Literature DB >> 24354438

Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.

E Hallert1, M Husberg, A Kalkan, T Skogh, L Bernfort.   

Abstract

OBJECTIVES: To calculate total costs over 6 years after diagnosis of early rheumatoid arthritis (RA).
METHOD: In the longitudinal prospective multicentre TIRA study, 239 patients from seven units, diagnosed in 1996-98, reported regularly on health-care utilization and the number of days lost from work. Costs were obtained from official databases and calculated using unit costs (Swedish kronor, SEK) from 2001. Indirect costs were calculated using the human capital approach (HCA). Costs were inflation adjusted to Euro June 2012, using the Swedish Consumer Price Index and the exchange rate of June 2012. Statistical analyses were based on linear mixed models (LMMs) for changes over time.
RESULTS: The mean total cost per patient was EUR 14,768 in year 1, increasing to EUR 18,438 in year 6. Outpatient visits and hospitalization decreased but costs for surgery increased from EUR 92/patient in year 1 to EUR 444/patient in year 6. Drug costs increased from EUR 429/patient to EUR 2214/patient, mainly because of the introduction of biologics. In year 1, drugs made up for 10% of direct costs, and increased to 49% in year 6. Sick leave decreased during the first years but disability pensions increased, resulting in unchanged indirect costs. Over the following years, disability pensions increased further and indirect costs increased from EUR 10,284 in year 1 to EUR 13,874 in year 6. LMM analyses showed that indirect costs were unchanged whereas direct costs, after an initial fall, increased over the following years, leading to increasing total costs.
CONCLUSIONS: In the 6 years after diagnosis of early RA, drug costs were partially offset by decreasing outpatient visits but indirect costs remained unchanged and total costs increased.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24354438     DOI: 10.3109/03009742.2013.835442

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  The burden of disease in rheumatoid arthritis.

Authors:  Till Uhlig; Rikke H Moe; Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

2.  Paid expenditures and productivity costs associated with permanent disability pensions in patients with spinal disorders: Nationwide Finnish Register-based Study, 1990-2010.

Authors:  Tom Asklöf; Janne Martikainen; Hannu Kautiainen; Maija Haanpää; Ilkka Kiviranta; Timo Pohjolainen
Journal:  Eur Spine J       Date:  2015-01-30       Impact factor: 3.134

3.  Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study.

Authors:  Kanta Kumar; Karim Raza; Peter Nightingale; Robert Horne; Sarah Chapman; Sheila Greenfield; Paramjit Gill
Journal:  BMC Musculoskelet Disord       Date:  2015-12-29       Impact factor: 2.362

4.  The use of administrative health care databases to identify patients with rheumatoid arthritis.

Authors:  John G Hanly; Kara Thompson; Chris Skedgel
Journal:  Open Access Rheumatol       Date:  2015-11-06

5.  The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study.

Authors:  Frank R Ernst; Peri Barr; Riad Elmor; Walter Sandulli; Lionel Thevathasan; Arnold B Sterman; Jessica Goldenberg; Kevin Vora
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

Review 6.  Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors.

Authors:  Toshio Tanaka; Yoshihiro Hishitani; Atsushi Ogata
Journal:  Biologics       Date:  2014-04-07

7.  Dispositional Affect in Unique Subgroups of Patients with Rheumatoid Arthritis.

Authors:  Danielle B Rice; Swati Mehta; Janet E Pope; Manfred Harth; Allan Shapiro; Robert W Teasell
Journal:  Pain Res Manag       Date:  2016-03-03       Impact factor: 3.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.